Can you get medical cannabis for Parkinson's disease in the UK?

Parkinson's disease is considered by UK specialists in selected cases, and the important detail is which symptoms. The trial evidence points to non-motor symptoms — anxiety and sleep — rather than to tremor or stiffness, which is the opposite of what most people expect.

Is Parkinson's disease treated with medical cannabis in the UK?

It is assessed in selected cases by private specialists, and it is not an NHS treatment for Parkinson's. Nothing is licensed for it, and NICE guideline NG71 on Parkinson's does not recommend cannabis-based medicines.

Where it is considered, the target is usually a specific troublesome symptom rather than the disease as a whole. In practice that means the non-motor symptoms that respond poorly to dopaminergic treatment: anxiety, disturbed night-time sleep, pain, and sometimes nausea. Motor symptoms — tremor, rigidity, bradykinesia — are managed with levodopa and related medicines, and there is no good evidence that a cannabis-based medicine improves them.

Parkinson's medicines are timed and titrated carefully, and small changes have large effects. Nothing on this page should be added, changed or stopped without your Parkinson's specialist or nurse being part of the decision.

What the evidence actually shows

The best-designed study in Parkinson's used a synthetic cannabinoid rather than a plant-derived product, and found a modest effect on non-motor symptoms rather than motor ones.

The NMS-Nab study was a randomised, placebo-controlled, double-blind trial with an enriched enrolment randomised withdrawal design, testing nabilone for non-motor symptoms in Parkinson's disease. It reported a significant advantage for nabilone on the MDS-UPDRS Part I score, with the effect driven mainly by improvements in anxious mood and night-time sleep problems. It was a small study, in a selected group of responders, over a short period.

Beyond that, evidence in Parkinson's is largely observational or from studies too small to draw conclusions from. Cannabidiol has been studied for Parkinson's-related psychosis and anxiety in early trials, without results that have changed practice.

What a specialist will want to see

There is no UK list of qualifying conditions, so nothing here entitles you to a prescription. A specialist works through your history and decides whether a monitored trial is justified for you. For Parkinson's disease they will typically look at:

• How long you have had Parkinson's, and who manages your treatment
• Which symptom you actually want addressed — anxiety, sleep, pain, nausea — rather than Parkinson's as a whole
• Your current medication regimen and timings, since these are easily destabilised
• Whether you have had hallucinations, delusions or confusion, which change the risk calculation substantially
• Your blood pressure, including postural drops, and your falls history
• Cognitive changes, which are common in Parkinson's and can be worsened by THC

The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?

Risks and reasons a specialist may say no

Parkinson's carries specific risks that make this a more cautious decision than in most conditions. Postural hypotension and falls are common already, and dizziness and sedation add to both.

Hallucinations and confusion occur in Parkinson's, particularly in later stages and with some Parkinson's medicines. THC can precipitate or worsen them, and a history of Parkinson's-related psychosis would normally rule out THC-containing treatment. Cognitive impairment is a further consideration. A specialist will want your Parkinson's team involved rather than prescribing in parallel, because the interaction with your existing regimen matters more than the medicine alone.

How medical cannabis is thought to help

Cannabis-based medicines act on the endocannabinoid system, a signalling network found throughout the brain, nervous system and immune cells that helps regulate mood, sleep, pain, appetite and movement. That broad role is why these medicines are studied across such different conditions — but a plausible mechanism is not the same as proven benefit, and the two should not be confused.

The two most studied plant compounds behave very differently. THC is intoxicating and acts directly on cannabinoid receptors; cannabidiol (CBD) is not intoxicating and works more indirectly. In Parkinson's the useful signal from trials concerns non-motor symptoms such as anxiety and sleep, rather than tremor or stiffness. Our guides on the endocannabinoid system and THC and CBD explain the difference in more detail.

It is worth being clear about what this does not mean. Parkinson's is driven by loss of dopamine-producing cells, and a cannabis-based medicine does nothing to change that. Where it is considered at all, it is aimed at a specific troublesome symptom, not at the disease.

What treatment involves in practice

Nothing is licensed for Parkinson's, so any treatment here is unlicensed and carried on specialist responsibility with your informed consent. If a specialist decides a monitored trial is justified, it starts at a low dose and is increased slowly — titrated — while benefit is weighed against side effects.

Products are usually oils or capsules taken by mouth, which act more slowly and last longer, or dried flower for vaporising, which acts faster; smoking is never a medical route. In Parkinson's the choice is made especially carefully because sedation, dizziness and blood-pressure drops add to an already raised falls risk. How the format and dose are chosen is set out in how a dose is decided and adjusted and how cannabis-based medicines are taken.

Follow-up reviews check how you are responding and whether side effects are tolerable, and the plan is adjusted — or stopped — accordingly. Benefit is judged over weeks rather than a single dose, as how long cannabis medicines take to work explains. Treatment that is not clearly helping is stopped rather than continued indefinitely, and your Parkinson's regimen stays under your specialist or nurse throughout, since it is easily destabilised.

Questions worth asking your specialist

A good assessment is a two-way conversation. Whether treatment turns out to suit you or not, these are sensible questions to bring, alongside the practical guides on driving, work and drug testing, and travelling abroad:

• Which symptom are we actually trying to improve — anxiety, sleep, pain — and how will we measure it?
• Given my falls risk and blood pressure, is a monitored trial reasonable for me?
• How will this interact with my Parkinson's medicines and their timing?
• Given my history, is there any risk of hallucinations or confusion with a THC-containing product?
• At what point would we agree the treatment is not helping and stop it?

If you want to take this further

The useful next step is a proper assessment, not a better list. Gather your diagnosis, the treatments you have already tried and what happened with each, and your current medicines — that is what a specialist needs in order to give you a straight answer.

The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If Parkinson's disease is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.

Patient guide · Written by the Flora House editorial team · Last reviewed: 7 October 2026